This statistic shows the amount of registrations of newly diagnosed cases of stomach cancer in England in 2022, by age group. With a total of *** cases in 2022, the age group most affected by stomach cancer in terms of the number of cases was men aged 75 to 79 years. It should be noted that the number of people in England in each age group varies and is therefore not necessarily a reflection of susceptibility to this cancer.

Aizawl district in the eastern state of Mizoram in India had age adjusted incidence rate of stomach cancer cases among male of over ** cases per million male adults between the years 2012 and 2016. Whereas, the age incidence rate of stomach cancer among women in that region was over ** cases per million females in the country.

Mortality from stomach cancer (ICD-10 C16 equivalent to ICD-9 151). To reduce deaths from stomach cancer. Legacy unique identifier: P00671

In 2019, nearly *** percent of all men, as well as more than *** percent of all women diagnosed with stomach cancer were between 65 to 69 years old. Meanwhile, only **** percent of all boys and **** percent of all girls and teens under 19 years old had the same condition.

Deaths from stomach cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

ObjectivesStomach cancer is one of the leading causes of cancer death, and its epidemiologic characteristics are regionally heterogeneous worldwide. The BRICS nations (Brazil, Russian Federation, India, China, and South Africa) have markedly increasing influences on the international stage. We aim to investigate time trends in stomach cancer mortality among the BRICS countries from 1982 to 2021.MethodsData for this study were obtained from the Global Burden of Disease (GBD) 2021 public dataset to investigate the deaths, all-age mortality rate, and age-standardized mortality rate (ASMR) of stomach cancer. The age-period-cohort (APC) model was employed to estimate net drift, local drift, age-specific curves, and period (cohort) relative risks, and the Bayesian generalized linear model was employed to evaluate the relationship between food intake and mortality rate.ResultsIn 2021, there were approximately 572,000 stomach cancer deaths across the BRICS, accounting for 59.9% of global death. Russian Federation exhibited the most significant reduction in ASMR of stomach cancer among the BRICS. In contrast, China continued to report the highest number of stomach cancer deaths. The risk of mortality associated with stomach cancer exhibited a marked increase with advancing age, both within these countries and at the global level. PUFA, sodium, calcium and trans fat may have an impact on the mortality rate of stomach cancer. Favorable trends in period and birth cohort effects were observed in these five nations over the past decades.ConclusionBRICS countries have made varying progress in reducing stomach cancer mortality. Given the diverse environments, it is recommended to progressively develop customized stomach cancer prevention strategies, utilizing available resources. Healthcare services should be extended to all age groups, with a particular emphasis on vulnerable populations.

Years of Life Lost (YLL) as a result of death from stomach cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

BackgroundStomach cancer is a significant health problem in many countries. But healthcare needs of adolescents and young adults (AYAs) stomach cancer patients have been historically neglected. An accurate appraisal of the burden of AYA stomach cancer is crucial to formulating effective preventive strategies. In this study, we report the most recent estimates of AYA stomach cancer burden concerning socio-demographic index (SDI) in 204 countries and territories between 1990 and 2019.MethodsEstimates from the Global Burden of Disease study 2019 were used to analyze incidence, mortality, and disability-adjusted life years (DALYs) due to AYA stomach cancer at global, regional, and national levels. Association between AYA stomach cancer burden and SDI were investigated. All estimates are reported as absolute numbers and age-standardized rates, which were standardized to the GBD world population and reported per 100,000 population.ResultsIn 2019, there were 49,000 incident cases, 27,895 deaths, and 1.57 million DALYs due to AYA stomach cancer globally. The highest age-standardized incidence rate occurred in East Asia [2.42 (women) and 4.71 (men) per 100,000 person-years] and high-income Asia Pacific [3.16 (women) and 2.61 (men) per 100,000 person-years]. Age-standardized death [1.53 (women) and 2.65 (men) per 100,000 person-years] and DALY [150.96 (women) and 87.13 (men) per 100,000 person-years] rates were highest in Oceania. Compared with 1990, in 2019 more than 1,075 more incident cases of AYA stomach cancer were estimated with a decrease of 7,784 deaths. Despite the increase in absolute number of incident cases, the worldwide age-standardized rates of AYA stomach cancer (incidence, deaths, and DALYs) have declined since 1990. The drop in the disease burden was associated with an improved SDI. Globally, 24.41% of the age-standardized DALYs were attributable to a high-sodium diet in both sexes combined, and 0.57% of the age-standardized DALYs were attributable to smoking in men.ConclusionThe global burden of AYA stomach cancer is substantial, especially in developing regions. Capacity-building activities for AYA stomach cancer will benefit the younger generation and population health worldwide.

Legacy unique identifier: P00670

In 2020, the mortality rate for stomach cancer was *** per 100,000 population among females in Canada. This statistic displays the age-standardized mortality rate of stomach cancers among females in Canada between 1988 and 2020 with forecasts from 2021 to 2023.

Table D. Age-specific stomach cancer deaths and the corresponding population, birth cohort and survey years in the period 1987-2016 in Lithuania. Women

This publication reports on newly diagnosed cancers registered in England during 2022. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document. Cancer registration estimates are provided for: • Incidence of cancer using groupings that incorporate both the location and type of cancer by combinations of gender, age, deprivation, and stage at diagnosis (where appropriate) for England, former Government office regions, Cancer alliances and Integrated care boards • Incidence and mortality (using ICD-10 3-digit codes) by gender and age group for England, former Government office regions, Cancer alliances and Integrated care boards This publication will report on 2022 cancer registrations only, trends will not be reported as the required re-stated populations for 2012 to 2020 are not expected to be published by the Office of National Statistics (ONS) until Winter 2024.

Table S3(A-D) shows country- and sex-specific data on new cases, person-years, crude incidence rates (CR), age-standardized incidence rates (ASIR), confidence intervals (LCIa, UCIa), and variance for non-cardia gastric cancer (NCGC) and cardia gastric cancer (CGC) in the whole and young (

In 2022, over 9.1 thousand people in England were diagnosed with esophageal cancer. The most affected age group was among those aged 75 to 79 years with 1,152 diagnoses in men of this age and 488 cases for women. The esophagus is also known as the gullet and is the tube that carries food to the stomach. Lifestyles which increase risk of developing esophageal cancer Certain harmful behaviors can increase the risk of a person developing esophageal cancer such as smoking or drinking excessive amounts of alcohol according to the NHS. As of 2022, 14 percent of men in England were regular smokers as well as 11 percent of women. Additionally, a study from 2022 found that many age groups, men in particular, exceed the recommended units of alcohol consumption of 1 units on an average week. Another aspect is diet Having a healthy diet is also an extra way to abet esophageal cancer, in particular the consumption of fruit and vegetables. The recommend advice is to consume at least five portions of fruit and vegetables per day. In 2018/19, among adults in England, 30 percent of women and 25 percent of men declared that they consume five portions or more per day. On the contrary, nine and seven percent of men and women respectively in England reported consuming no fruit or vegetables on a typical day.

The global stomach cancer drug market is a dynamic landscape characterized by significant growth potential. While precise market size figures for 2019-2024 are unavailable, we can infer substantial growth based on the provided forecast period (2025-2033) and a projected Compound Annual Growth Rate (CAGR). Assuming a conservative CAGR of 5% (a reasonable estimate given the prevalence of stomach cancer and ongoing research and development in targeted therapies), the market size in 2025 could be estimated at approximately $5 billion USD, considering the involvement of major pharmaceutical players like Pfizer, Eli Lilly, and AstraZeneca. This suggests a substantial market opportunity, driven primarily by the increasing incidence of stomach cancer globally, particularly in developing nations. The market is further propelled by advancements in targeted therapies, immunotherapy, and improved diagnostic tools leading to earlier detection and better treatment outcomes. This is creating demand for innovative drugs with improved efficacy and reduced side effects. However, market growth is tempered by several factors. High treatment costs associated with novel therapies create accessibility challenges, particularly in low- and middle-income countries. Moreover, the heterogeneity of stomach cancer, with diverse subtypes and varying responses to treatment, poses ongoing hurdles for drug development. Despite these challenges, the continued investment in research and development by leading pharmaceutical companies, coupled with an expanding understanding of the disease's molecular mechanisms, positions the stomach cancer drug market for sustained growth throughout the forecast period. The segmentation of the market, although not specified, likely includes various treatment modalities (chemotherapy, targeted therapy, immunotherapy) and drug classes (e.g., anti-angiogenic agents, EGFR inhibitors), further highlighting its complexity and opportunity.

Supplementary Table S6 shows ASIR trends of NCGC among Chinese males aged 50 and older from 1988 to 2017.

BackgroundColon cancer, esophageal cancer, and stomach cancer are the common causes of morbidity and mortality in China, Japan, the US., and India. The current study aims to assess and compare secular trends of the mortality of gastrointestinal cancers during the period, 1990–2017 in age-specific, time period, and birth cohort effects.MethodWe used the Joinpoint model to collect age-standardized mortality rates (ASMRs) for four countries. We designed an age-period-cohort (APC) analysis to estimate the independent effects on the mortality of three types of cancers.ResultThe Joinpoint model shows that in addition to the death rate of esophageal cancer in Japan, the ASMR of esophageal cancer and stomach cancer in other countries declined rapidly. The APC analysis presented a similar pattern of age effect between four countries for colon cancer and stomach cancer, which increased from 20 to 89 age groups. Differently, the period effect rapidly increased for esophageal cancer and stomach cancer in the US, and the period effect in China presented a declining volatility, showing its highest value in 2007. In future, highest mortality trends are likely to occur in China.ConclusionTherefore, the obvious increase in colon cancer recommended that earlier tactics must be performed to reduce mortality from specific causes from 2018 to 2027.

The global Stomach Cancer Drug Therapy market size is projected to reach USD 24.5 billion by 2033, exhibiting a CAGR of 12.4% during the forecast period. Increasing prevalence of stomach cancer, rising demand for targeted therapies, and favorable reimbursement policies are driving market growth. Furthermore, advancements in research and development and increasing healthcare expenditure are expected to boost market demand. Key market players include Pfizer, Novartis International, Eli Lilly and Company, Bristol Myers Squibb Company, Teva Pharmaceutical Industries, F. Hoffmann La Roche, Mylan NV, Celltrion Healthcare, Merck & Co., and Teva Pharmaceutical Industries. The market is characterized by intense competition, with major players focusing on product innovation, strategic partnerships, and geographical expansion to maintain their market share. Partnerships between pharmaceutical companies and research institutions are also fostering the development of novel therapies and expanding the market landscape.

BackgroundNotable geographic and temporal variations in the prevalence and genotypes of Helicobacter pylori, in relation to gastric pathologies, have been observed; however, their significance and trends in African populations is scarcely described. The aim of this study, was to investigate the association of H. pylori and its respective CagA and vacuolating cytotoxin A (VacA) genotypes with gastric adenocarcinoma, and to describe the trends of H. pylori genotypes over an 8-year period (2012–2019).Materials and methodsA total of 286 samples of gastric cancer cases and benign controls (one-to-one matching), from three main cities in Kenya, between 2012 and 2019 were included. Histologic evaluation, and CagA and VacA genotyping using PCR, was performed. Distribution of H. pylori genotypes was presented in proportions. To determine association, a univariate analysis was conducted using a Wilcoxon rank sum test for continuous variables, and a Chi-squared test or Fisher’s exact test for categorical data.ResultsThe VacA s1m1 genotype was associated with gastric adenocarcinoma, {odds ratio (OR) = 2.68 [confidence interval (CI) of 95%: 0.83–8.65]; p = 0.108}, whilst VacA s2m2 was associated with a reduced probability of gastric adenocarcinoma [OR = 0.23 (CI 95%: 0.07–0.78); p = 0.031]. No association between cytotoxin associated gene A (CagA) and gastric adenocarcinoma was observed.ConclusionOver the study period, an increase in all genotypes of H. pylori was seen, and although no predominant genotype was noted, there was significant year-to-year variation, with VacA s1 and VacA s2 showing the greatest variation. VacA s1m1 and VacA s2m2 were associated with increased, and reduced risk of gastric cancer, respectively. Intestinal metaplasia and atrophic gastritis did not appear to be significant in this population.

Māori, the indigenous people of New Zealand, experience disproportionate rates of stomach cancer, compared to non-Māori. The overall aim of the study was to better understand the reasons for the considerable excess of stomach cancer in Māori and to identify priorities for prevention. Māori stomach cancer cases from the New Zealand Cancer Registry between 1 February 2009 and 31 October 2013 and Māori controls, randomly selected from the New Zealand electoral roll were matched by 5-year age bands to cases. Logistic regression was used to estimate odd ratios (OR) and 95% confidence intervals (CI) between exposures and stomach cancer risk. Post-stratification weighting of controls was used to account for differential non-response by deprivation category. The study comprised 165 cases and 480 controls. Nearly half (47.9%) of cases were of the diffuse subtype. There were differences in the distribution of risk factors between cases and controls. Of interest were the strong relationships seen with increased stomach risk and having >2 people sharing a bedroom in childhood (OR 3.30, 95%CI 1.95–5.59), testing for H pylori (OR 12.17, 95%CI 6.15–24.08), being an ex-smoker (OR 2.26, 95%CI 1.44–3.54) and exposure to environmental tobacco smoke in adulthood (OR 3.29, 95%CI 1.94–5.59). Some results were attenuated following post-stratification weighting. This is the first national study of stomach cancer in any indigenous population and the first Māori-only population-based study of stomach cancer undertaken in New Zealand. We emphasize caution in interpreting the findings given the possibility of selection bias. Population-level strategies to reduce the incidence of stomach cancer in Māori include expanding measures to screen and treat those infected with H pylori and a continued policy focus on reducing tobacco consumption and uptake.